GossetGo beyond retrieval
Leverage accurate, calibrated forecasts trusted by top-30 pharma.
Forecasts evaluated against observed outcomes, using point-in-time data.
Before running a trial or acquiring an asset, you need an accurate estimate of how likely the drug is to reach approval. Other platforms only estimate whether a trial meets its endpoints; Gosset also forecasts whether the drug progresses to the next stage and is ultimately approved. Our models train on proprietary trial progression, trial design, and drug performance data, so they account for the full regulatory and competitive landscape.
Knowing when a trial will read out is essential for portfolio strategy, competitive intelligence, and investing. Sponsor-registered completion dates are optimistic by design and are often not revised until long after a timeline has slipped. Gosset's model learns from how thousands of comparable trials actually progressed. Our estimates land a median of 47 days closer to the actual date than sponsor estimates.
Licensing, M&A, and investment decisions hinge on an accurate estimate of a drug asset's risk-adjusted net present value (rNPV). Gosset's asset valuation model leverages our best-in-class data on drugs' probability of getting approved, scientific risk, comparable deals, market size, competitive landscape, and patent runway to deliver informed estimates. Each estimate is paired with a report covering the underlying evidence.